Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the StockThe Motley Fool • 10/12/26
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.The Motley Fool • 10/12/26
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending StockZacks Investment Research • 10/09/26
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks24/7 Wall Street • 10/09/26
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityPRNewsWire • 10/09/26
Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare PlatformThe Motley Fool • 10/08/26
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?Zacks Investment Research • 10/08/26
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge cautionMarket Watch • 10/08/26
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A PremiumSeeking Alpha • 10/08/26
Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond ZepboundThe Motley Fool • 10/07/26
Lilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound24/7 Wall Street • 10/07/26